Download PDF
CC BY-NC-ND 4.0 · Journal of Digestive Endoscopy 2020; 11(04): 290-292
DOI: 10.1055/s-0039-3400709
Case Report

Raised CA19-9 in Autoimmune Pancreatitis

Sridhar Sundaram
1   Department of Gastroenterology, Seth Gordhandas Sunderdas Medical College, King Edward Memorial Hospital, Mumbai, Maharashtra, India
,
Deepak Kumar Gupta
1   Department of Gastroenterology, Seth Gordhandas Sunderdas Medical College, King Edward Memorial Hospital, Mumbai, Maharashtra, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Autoimmune pancreatitis (AIP) is a known autoimmune disorder of the pancreas, with a clinical presentation similar to that of carcinoma of the pancreas. CA19-9 levels can be the distinguishing feature between the two disorders. In rare instances, CA19-9 may be elevated in AIP. Elevation of levels of more than 1,000 U/mL has been reported in only one case series previously. Here we report a rare instance of CA19-9 more than 1,000 U/mL in a case of AIP and its subsequent management.

Keywords

autoimmune pancreatitis - CA19-9 - carcinoma of the pancreas


Publication History

Article published online:
27 May 2020

© 2020. Society of Gastrointestinal Endoscopy of India. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Chang MC, Liang PC, Jan S. et al. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels. Pancreatology 2014; 14 (05) 366-372
    CrossrefPubMedGoogle Scholar
  • 2 Ito S, Gejyo F. Elevation of serum CA19-9 levels in benign diseases. Intern Med 1999; 38 (11) 840-841
    CrossrefPubMedGoogle Scholar
  • 3 Sheen-Chen SM, Sun CK, Liu YW. Eng HL, Ko SF, Kuo CH. Extremely elevated CA19-9 in acute cholangitis. Dig Dis Sci 2007; 52 (11) 3140-3142
    CrossrefPubMedGoogle Scholar
  • 4 De Marchi G, Paiella S, Luchini C, Capelli P, Bassi C, Frulloni L. Very high serum levels of CA 19-9 in autoimmune pancreatitis: Report of four cases and brief review of literature. J Dig Dis 2016; 17 (10) 697-702
    CrossrefPubMedGoogle Scholar
  • 5 Okazaki K, Chari ST, Frulloni L. et al. International consensus for the treatment of autoimmune pancreatitis. Pancreatology 2017; 17 (01) 1-6
    CrossrefPubMedGoogle Scholar
  • 6 Sah RP, Chari ST, Pannala R. et al. Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology 2010; 139 (01) 140-148, quiz e12–e13
    CrossrefPubMedGoogle Scholar
  • 7 Gupta R, Khosroshahi A, Shinagare S. et al. Does autoimmune pancreatitis increase the risk of pancreatic carcinoma?: a retrospective analysis of pancreatic resections. Pancreas 2013; 42 (03) 506-510
    CrossrefPubMedGoogle Scholar
  • 8 Ikeura T, Miyoshi H, Shimatani M, Uchida K, Takaoka M, Okazaki K. Long-term outcomes of autoimmune pancreatitis. World J Gastroenterol 2016; 22 (34) 7760-7766
    CrossrefPubMedGoogle Scholar